These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 30723035)

  • 21. Efficacy and Safety of Melphalan, Cyclophosphamide and Dexamethasone (MCD) as a Salvage Treatment for Patients with Relapsed/Refractory Multiple Myeloma.
    Lee SS; Lee JJ
    Chonnam Med J; 2019 Jan; 55(1):25-30. PubMed ID: 30740337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma.
    Mateos MV; Weisel K; Terpos E; Delimpasi S; Kastritis E; Zamagni E; Delforge M; Ocio E; Katodritou E; Gay F; Larocca A; Leleu X; Otero PR; Schjesvold F; Cavo M; Dimopoulos MA
    Haematologica; 2024 Jul; 109(7):2337-2340. PubMed ID: 38385280
    [No Abstract]   [Full Text] [Related]  

  • 23. Flow cytometry based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment.
    Raja KR; Plasil M; Rihova L; Pelcova J; Adam Z; Hajek R
    Cytometry B Clin Cytom; 2013 Jul; ():. PubMed ID: 23893930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Double-drug loading upconversion nanoparticles for monitoring and therapy of a MYC/BCL6-positive double-hit diffuse large B-cell lymphoma.
    Yang Y; Chen R; Gong Y; Yang W; Li K; Fan W; Gou S; Gao P; He T; Cai K
    Biomaterials; 2022 Aug; 287():121607. PubMed ID: 35696785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development.
    Iftikhar A; Hassan H; Iftikhar N; Mushtaq A; Sohail A; Rosko N; Chakraborty R; Razzaq F; Sandeep S; Valent JN; Kanate AS; Anwer F
    Antibodies (Basel); 2019 May; 8(2):. PubMed ID: 31544840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation-Results from the LenaMain Trial (NCT00891384).
    Boquoi A; Giagounidis A; Goldschmidt H; Heinsch M; Rummel MJ; Kröger N; Mai EK; Strapatsas J; Haas R; Kobbe G
    Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis.
    Patti F; Lo Fermo S
    Autoimmune Dis; 2011 Mar; 2011():961702. PubMed ID: 21547093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives.
    Kulig P; Milczarek S; Bakinowska E; Szalewska L; Baumert B; Machaliński B
    Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma.
    Swan D; Gurney M; Krawczyk J; Ryan AE; O'Dwyer M
    Hemasphere; 2020 Apr; 4(2):e350. PubMed ID: 32309787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
    Armoiry X; Connock M; Tsertsvadze A; Cummins E; Melendez-Torres GJ; Royle P; Clarke A
    Pharmacoeconomics; 2018 Sep; 36(9):1073-1081. PubMed ID: 29582405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How lenalidomide is changing the treatment of patients with multiple myeloma.
    Dimopoulos MA; Terpos E; Niesvizky R
    Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S23-35. PubMed ID: 23816163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of Cyclophosphamide "On Demand" to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma-A Retrospective Review of a Single-center Experience.
    Alahmadi M; Masih-Khan E; Atenafu EG; Chen C; Kukreti V; Tiedemann R; Trudel S; Reece DE
    Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):e195-e203. PubMed ID: 30723035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.
    Kotchetkov R; Masih-Khan E; Chu CM; Atenafu EG; Chen C; Kukreti V; Trudel S; Tiedemann R; Reece DE
    Cancer Med; 2017 Jan; 6(1):3-11. PubMed ID: 27860411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.
    Fouquet G; Tardy S; Demarquette H; Bonnet S; Gay J; Debarri H; Herbaux C; Guidez S; Michel J; Perrot A; Serrier C; Miljkovic D; Avet Loiseau H; Facon T; Hulin C; Leleu X
    Cancer; 2013 Oct; 119(20):3680-6. PubMed ID: 23921945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials.
    Knauf W; Aldaoud A; Losem C; Mittermueller J; Neise M; Niemeier B; Harde J; Trarbach T; Potthoff K
    Leuk Res; 2018 May; 68():90-97. PubMed ID: 29579627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma.
    Lund J; Gruber A; Lauri B; Duru AD; Blimark C; Swedin A; Hansson M; Forsberg K; Ahlberg L; Carlsson C; Waage A; Gimsing P; Vangsted AJ; Frølund U; Holmberg E; Gahrton G; Alici E; Hardling M; Mellqvist UH; Nahi H
    Cancer Med; 2018 Jun; 7(6):2256-2268. PubMed ID: 29673108
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.